Search
- MediaPress Release
GlaxoSmithKline update: A (H1N1) influenza vaccine development
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
First published: 14 May 2009
- MediaPress Release
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
GSK announced ,FDA has approved FLUARIX QUADRIVALENT Influenza Vaccine for the immunisation of patients to help prevent seasonal influenza
First published: 17 December 2012
- MediaPress Release
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GSK has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
First published: 03 April 2013
- MediaPress Release
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.
First published: 09 November 2009
- MediaPress Release
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months
First published: 06 March 2018
- MediaPress Release
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
GSK announced today that it has received a Complete Response letter from the FDA .
First published: 25 March 2013
- MediaPress Release
GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older
GSK announced the expanded indication for Fluarix Tetra has been approved in Europe.
First published: 15 February 2018
- MediaPress Release
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
First published: 02 February 2016
- MediaPress Release
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
An approval from the US Food and Drug Administration’s (FDA) Center
First published: 18 November 2016
- MediaPress Release
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Data support progression to phase III clinical trials.
First published: 12 September 2024